$GNPX
Genprex Inc Stock $gnpx

$gnpx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000143774923008847 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.960M	$3.497M	$12.30M
YoY Change	2.7%	59.25%	12.07%
% of Gross Profit
Research & Development	$5.310M	$3.319M	$11.51M
YoY Change	185.36%	-4.64%	33.72%
% of Gross Profit
Depreciation & Amortization	$4.016K	$6.080K	$25.58K
YoY Change	-40.33%	-12.52%	13.5%
% of Gross Profit
Operating Expenses	$5.310M	$6.822M	$11.51M
YoY Change	185.36%	20.04%	33.72%
Operating Profit	-$9.271M		-$23.83M
YoY Change	61.99%		21.58%
Interest Expense	$70.00K	$55.60K	$90.10K
YoY Change	7854.55%	5516.16%	1656.34%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$9.200M	-$6.766M	-$23.74M
YoY Change	60.77%	19.08%	21.15%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$9.203M	-$6.766M	-$23.74M
YoY Change	60.82%	19.08%	21.15%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.19		-$0.50
Diluted Earnings Per Share	-$0.19	-$0.14	-$0.50
COMMON SHARES
Basic Shares Outstanding	51.97M	48.03M	47.95M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.08M	$20.95M	$20.95M
YoY Change	-47.67%	-45.76%	-45.76%
Cash & Equivalents	$18.08M	$20.95M
Short-Term Investments
Other Short-Term Assets	$1.859M	$484.2K	$484.2K
YoY Change	66.67%	-5.31%	-5.31%
Inventory
Prepaid Expenses
Receivables	$0.00	$34.85K	$34.85K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$19.94M	$21.47M	$21.47M
YoY Change	-44.14%	-45.14%	-45.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.02K	$23.03K	$23.03K
YoY Change	-54.59%	-52.62%	-52.62%
Goodwill
YoY Change
Intangibles	$721.7K	$702.1K
YoY Change	12.03%	9.3%
Long-Term Investments
YoY Change
Other Assets	$3.359M	$3.589M	$21.82K
YoY Change	-8.34%	-2.3%	151.09%
Total Long-Term Assets	$3.378M	$3.612M	$3.612M
YoY Change	-8.86%	-2.96%	-2.96%
TOTAL ASSETS
Total Short-Term Assets	$19.94M	$21.47M	$21.47M
Total Long-Term Assets	$3.378M	$3.612M	$3.612M
Total Assets	$23.32M	$25.09M	$25.09M
YoY Change	-40.83%	-41.48%	-41.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.212M	$442.9K	$442.9K
YoY Change	76.56%	-54.49%	-54.49%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.835M	$2.810M	$2.810M
YoY Change	102.75%	77.27%	77.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.835M	$2.810M	$2.810M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$4.835M	$2.810M	$2.810M
YoY Change	102.75%	77.27%	77.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$112.0M	-$102.8M
YoY Change	33.78%	31.8%
Common Stock	$51.97K	$48.11K
YoY Change	8.55%	0.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.48M	$22.27M	$22.27M
YoY Change
Total Liabilities & Shareholders Equity	$23.32M	$25.09M	$25.09M
YoY Change	-40.83%	-41.48%	-41.48%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$9.203M	-$6.766M	-$23.74M
YoY Change	60.82%	19.08%	21.15%
Depreciation, Depletion And Amortization	$4.016K	$6.080K	$25.58K
YoY Change	-40.33%	-12.52%	13.5%
Cash From Operating Activities	-$6.932M	-$4.586M	-$17.78M
YoY Change	69.75%	42.52%	24.46%
INVESTING ACTIVITIES
Capital Expenditures	$19.63K	$20.00K	$0.00
YoY Change		-176.28%	-100.0%
Acquisitions
YoY Change
Other Investing Activities		$39.68K	$157.5K
YoY Change		-126.93%	-1486.18%
Cash From Investing Activities	-$19.63K	$19.68K	$97.73K
YoY Change	-290.2%	-111.34%	-216.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.426K
YoY Change			-99.97%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.081M	4.680K	$6.426K
YoY Change			-99.97%
NET CHANGE
Cash From Operating Activities	-$6.932M	-4.586M	-$17.78M
Cash From Investing Activities	-$19.63K	19.68K	$97.73K
Cash From Financing Activities	$4.081M	4.680K	$6.426K
Net Change In Cash	-$2.871M	-4.562M	-$17.67M
YoY Change	-29.51%	34.51%	-256.29%
FREE CASH FLOW
Cash From Operating Activities	-$6.932M	-$4.586M	-$17.78M
Capital Expenditures	$19.63K	$20.00K	$0.00
Free Cash Flow	-$6.952M	-$4.606M	-$17.78M
YoY Change	70.23%	44.32%	24.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48105962
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48105962
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47874708
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47874708
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79087198	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-20670102	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20664969	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5309817	usd
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5770386	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11081083	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5764642	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11074460	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6170439	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17251522	usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38244
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0772347
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3300 Bee Cave Road #650-227
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78746
CY2022	dei	City Area Code CityAreaCode	877
CY2022	dei	Local Phone Number LocalPhoneNumber	774-4679
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	GNPX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	66000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51974078
CY2022	dei	Auditor Firm AuditorFirmId	229
CY2022	dei	Auditor Name AuditorName	Daszkal Bolton LLP
CY2022	dei	Auditor Location AuditorLocation	Boca Raton, FL
CY2022Q4	us-gaap	Cash Cash	20954069	usd
CY2021Q4	us-gaap	Cash Cash	38628876	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34852	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	484224	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	511348	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	21473145	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	39140224	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23032	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48608	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	21818	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	8691	usd
CY2022Q4	gnpx	Research And Development Assets Noncurrent ResearchAndDevelopmentAssetsNoncurrent	2864937	usd
CY2021Q4	gnpx	Research And Development Assets Noncurrent ResearchAndDevelopmentAssetsNoncurrent	3022403	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	702095	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	642360	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3588850	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3673454	usd
CY2022Q4	us-gaap	Assets Assets	25085027	usd
CY2021Q4	us-gaap	Assets Assets	42862286	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	442925	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	973195	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2367362	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	612100	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2810287	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1585295	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48106	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	47874	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125054453	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	120316315	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-102827819	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79087198	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22274740	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	41276991	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25085027	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42862286	usd
CY2022	us-gaap	Revenues Revenues	0	usd
CY2021	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Depreciation Depreciation	25575	usd
CY2021	us-gaap	Depreciation Depreciation	22534	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11510074	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8970865	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12295070	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11676703	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	23830719	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	20670102	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-23830719	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-20670102	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	90098	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	5133	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-23740621	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20664969	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47952100
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47097251
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	30916490	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25677911	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	156045	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5191514	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20664969	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	41276991	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6426	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	163232	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4568712	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-23740621	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22274740	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-23740621	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20664969	usd
CY2022	us-gaap	Depreciation Depreciation	25575	usd
CY2021	us-gaap	Depreciation Depreciation	22534	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4731944	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5347559	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34852	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-127	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-27125	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	126795	usd
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	13127	usd
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-2050	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-530269	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	780226	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1755262	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	354344	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17778964	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14284924	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31700	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	59735	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	40735	usd
CY2022	gnpx	Payments For Proceeds From Research And Development Supplies PaymentsForProceedsFromResearchAndDevelopmentSupplies	-157465	usd
CY2021	gnpx	Payments For Proceeds From Research And Development Supplies PaymentsForProceedsFromResearchAndDevelopmentSupplies	11361	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	97731	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-83796	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6426	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25677911	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6426	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25677911	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17674807	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11309191	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38628876	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27319685	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20954069	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38628876	usd
CY2021Q4	us-gaap	Assets Assets	42862286	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1585295	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	47874	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	120316315	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	41276991	usd
CY2021	us-gaap	Depreciation Depreciation	22534	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8970865	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11676703	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	20670102	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	5133	usd
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47097251
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Use of Estimates</i></span></b></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	20679538	usd
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	38392885	usd
CY2022Q4	gnpx	Research And Development Assets Current ResearchAndDevelopmentAssetsCurrent	2864937	usd
CY2021Q4	gnpx	Research And Development Assets Current ResearchAndDevelopmentAssetsCurrent	3022403	usd
CY2022Q4	us-gaap	Other Commitment OtherCommitment	340000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2926927	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	gnpx	Stock Issued During Period Shares Exercise Of Cashless Warrants StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants	13643
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	116973
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	670889
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	677912	usd
CY2021	gnpx	Stock Issued During Period Shares Warrants Issued StockIssuedDuringPeriodSharesWarrantsIssued	86138
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48105962
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4967153	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2836916	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6100657	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	5770386	usd
	us-gaap	Costs And Expenses CostsAndExpenses	11081083	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	5744	usd
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2154747
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.37
CY2021	gnpx	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	50000
CY2021	gnpx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	5.29
CY2021	gnpx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	0
CY2021	gnpx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	0
CY2021	gnpx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	0
CY2021	gnpx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2204747
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.39
CY2022	gnpx	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	103000
CY2022	gnpx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	1.54
CY2022	gnpx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	146326
CY2022	gnpx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	3.79
CY2022	gnpx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	13643
CY2022	gnpx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	0.50
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2147778
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.32
CY2022Q4	gnpx	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	1901945
CY2022Q4	gnpx	Class Of Warrant Or Right Exercisable Exercise Price ClassOfWarrantOrRightExercisableExercisePrice	4.59
CY2022	gnpx	Stock Issued During Period Shares Exercise Of Cashless Warrants StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants	13643
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11374327
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2983666
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	66667
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	116973
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.02
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2519628
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	118507
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	670889
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y29D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M26D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6844069
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.81
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2519628
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.26
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	670889
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.01
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	118507
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8574301
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.35
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2983666
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.16
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	116973
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.02
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	66667
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.55
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11374327
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.08
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6718035
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.23
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	74281	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	68900000	usd
CY2022Q1	us-gaap	Assets Assets	39409431	usd
CY2022Q1	us-gaap	Liabilities Liabilities	2384817	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	47879	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121373750	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84397015	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	37024614	usd
CY2022Q2	us-gaap	Assets Assets	34565123	usd
CY2022Q2	us-gaap	Liabilities Liabilities	2153838	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	47898	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	122525045	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90161658	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	32411285	usd
CY2022Q3	us-gaap	Assets Assets	29945826	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2457311	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	48020	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	123744715	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96304220	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27488515	usd
CY2021Q1	us-gaap	Revenues Revenues	0	usd
CY2021Q1	us-gaap	Depreciation Depreciation	6730	usd
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2040226	usd
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3263741	usd
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	5310696	usd
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5310696	usd
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	879	usd
CY2021Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	47879597
CY2022Q2	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	0	usd
CY2022Q2	us-gaap	Depreciation Depreciation	6543	usd
	us-gaap	Depreciation Depreciation	13273	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6623	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	47893404
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	47892919
CY2022Q3	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	0	usd
CY2022Q3	us-gaap	Depreciation Depreciation	6224	usd
	us-gaap	Depreciation Depreciation	19497	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3157731	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8124884	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3006484	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9107141	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	6170439	usd
	us-gaap	Costs And Expenses CostsAndExpenses	17251522	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	27877	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	34500	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6142562	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17217022	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2022Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	47984724
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	47919626

Files In Submission

Name	View Source	Status
gnpx-20221231_pre.xml	Edgar Link	unprocessable
0001437749-23-008847-index-headers.html	Edgar Link	pending
0001437749-23-008847-index.html	Edgar Link	pending
0001437749-23-008847.txt	Edgar Link	pending
0001437749-23-008847-xbrl.zip	Edgar Link	pending
a1new.jpg	Edgar Link	pending
a2new.jpg	Edgar Link	pending
acclaim3_850.jpg	Edgar Link	pending
attd_graphs.jpg	Edgar Link	pending
diabetes3_850.jpg	Edgar Link	pending
diabetes4_850.jpg	Edgar Link	pending
diabetes5_850.jpg	Edgar Link	pending
ex_451285.htm	Edgar Link	pending
ex_451286.htm	Edgar Link	pending
ex_451287.htm	Edgar Link	pending
ex_451288.htm	Edgar Link	pending
ex_451289.htm	Edgar Link	pending
figure1.jpg	Edgar Link	pending
figure2.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gnpx-20221231.xsd	Edgar Link	pending
gnpx20221231_10k.htm	Edgar Link	pending
gpx002new.jpg	Edgar Link	pending
gylze0pdymuz000002.jpg	Edgar Link	pending
gylze0pdymuz000003.jpg	Edgar Link	pending
gylze0pdymuz000004.jpg	Edgar Link	pending
gylze0pdymuz000006.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oncoprexlnp_850.jpg	Edgar Link	pending
pipelinev20_850.jpg	Edgar Link	pending
gnpx-20221231_def.xml	Edgar Link	unprocessable
gnpx-20221231_lab.xml	Edgar Link	unprocessable
gnpx-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
gnpx20221231_10k_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
reqorsatarceva_850v1.jpg	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GNPX
Genprex Inc Stock $gnpx

2023 Q1 Form 10-K Financial Statement

#000143774923008847 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNPX Genprex Inc Stock $gnpx

2023 Q1 Form 10-K Financial Statement

#000143774923008847 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNPX
Genprex Inc Stock $gnpx